跳至主要内容
临床试验/NCT00545116
NCT00545116已完成2 期

Short-term Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women: a Randomized Placebo-controlled Trial

Société des Produits Nestlé (SPN)1 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2007年10月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
144
试验地点
1
主要终点
Percentage change from baseline for bone formation (serum P1NP & osteocalcin) and bone resorption (urinary NTX & serum CTX) markers

研究概览

简要总结

The primary objective of this clinical trial is to determine the effects of hesperidin on biochemical markers of bone in post-menopausal women.

The secondary objectives are:

  • To investigate changes in bone formation and bone resorption markers in response to hesperidin intake
  • To compare the efficacy of hesperidin in a milk versus biscuit
  • To collect safety information of hesperidin consumption in a human trial

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •Community dwelling women
  • •More than 4 years post-menopause (natural or surgical)
  • •Generally healthy as determined by standard medical assessment on physical and mental health
  • •Willing to comply with the study procedures
  • •Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data
  • •Having received both oral and written explanations about the study
  • •Having provided her written informed consent

排除标准

  • •Intestinal or severe metabolic diseases / disorders such as diabetes, renal, hepatic or pancreatic diseases / disorders, ulcer, hyperthyroidism, malignance, chronic malnutrition
  • •Have had major gastrointestinal surgery
  • •On therapy with drugs known to interfere with bone metabolism such as steroids, vitamin D or its derivatives, bisphosphonates, strontium ranelate, PTH, calcitonin, raloxifene, etc.
  • •Had sustained a fracture in the preceding 12 months
  • •On hormone replacement therapy (HRT) in the previous 3 months before entering the study
  • •Taking medications containing hesperidin (e.g.Daflon) or known to interfere with hesperidin (statins, therapy for circulatory disorders, anti-depressants)
  • •Known to have allergic reactions to citrus-containing foods
  • •Baseline calcium intake less than 500 mg/day
  • •Have an alcohol intake > 2 glasses of wine per day (3dL/day), or > 2 beers (3dL/d) or > 1 shot glass of hard alcohol
  • •Heavy smoker (more than 10 cigs a day)
  • •Special dietary habits (vegetarians)
  • •Phytoestrogens or antioxidants (dietary supplements) consumption

研究组 & 干预措施

d

Placebo Comparator

Placebo carrier 2: liquid skim milk with the same nutrient composition and appearance as the active milk carrier but minus hesperidin

干预措施: Hesperidin (Other)

c

Placebo Comparator

Placebo carrier 1: biscuit with the same nutrient composition and appearance as the active biscuit carrier but minus hesperidin

干预措施: Hesperidin (Other)

b

Experimental

Active carrier 2: liquid skim milk providing 250 mg hesperidin/serve (200 ml) and containing around 300 mg calcium/serving

干预措施: Hesperidin (Other)

a

Experimental

Active carrier 1: biscuit providing 250 mg hesperidin per piece(6g)

干预措施: Hesperidin (Other)

结局指标

主要结局

Percentage change from baseline for bone formation (serum P1NP & osteocalcin) and bone resorption (urinary NTX & serum CTX) markers

时间窗: Six months

次要结局

  • Full blood biochemistry analyses including lipid profile(6 months)
  • Percentage change from baseline for osteoarthritis markers (CTX2 and others)(6 months)

研究者

发起方
Société des Produits Nestlé (SPN)
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验